Articles tagged with: Bone Disease

News»

[ by | Mar 30, 2011 2:41 pm | 3 Comments ]
Aredia Does Not Prevent Disease Progression In Smoldering Myeloma Patients

According to a recent study, the bisphosphonate Aredia reduces skeletal-related events, such as bone lesions and bone fractures, in patients with smoldering multiple myeloma; however, it does not prevent disease progression to symptomatic myeloma.

According to the study authors, these findings are consistent with the findings of previous studies that had shorter follow-up times.

Bone disease is frequently associated with multiple myeloma and can cause bone pain and fractures (see related Beacon news). While the symptoms of bone disease can be treated with radiation therapy and surgical procedures, bisphosphonates …

Read the full story »

News»

[ by | Mar 7, 2011 4:12 pm | 3 Comments ]
Kyphoplasty Is More Effective Than Non-Surgical Care In Multiple Myeloma Patients With Spinal Fractures

Results of a recent study suggest that balloon kyphoplasty provides better pain relief and more back-specific mobility one month after treatment than non-surgical care in multiple myeloma patients and other cancer patients with spinal fractures.

Based on these findings, the study authors suggested that balloon kyphoplasty be considered as an early treatment option for cancer patients with vertebral compression fractures.

One of the hallmarks of multiple myeloma is bone disease, which is noted by bone pain, bone fractures or lesions, and increased calcium levels. Myeloma bone disease often causes bone …

Read the full story »

NewsFlash »

[ by | Feb 14, 2011 4:09 pm | One Comment ]

Bafetinib May Prevent Bone Loss For Cancer Patients – A series of preclinical studies indicate that the drug bafetinib (INNO-406) inhibits bone deterioration in cancer patients who are at high risk for bone loss, including multiple myeloma patients. Although bafetinib is being developed by CytRX for the treatment of certain types of leukemia, the latest preclinical studies showed that bafetinib also suppresses the activity of bone cells that break down bone and cause fractures, bone pain, and high blood calcium levels. Bafetinib is also being tested in ongoing clinical trials for effectiveness against prostate cancer and brain tumors.  For more information, please see the CytRx Corporation press release.

Phase 2 Study Will Examine Curcumin’s Ability To Reduce Myeloma Symptoms During Maintenance Therapy – M.D. Anderson Cancer Center in Houston will begin a Phase 2 clinical trial to determine whether curcumin, the active ingredient in the Indian spice turmeric, can reduce symptoms of myeloma for patients taking Revlimid (lenalidomide) as maintenance therapy. Researchers will assess the effects of curcumin on pain, fatigue, bone aches, numbness, and disturbed sleep. The trial, which is not yet enrolling patients, will begin in June and include approximately 70 participants. For more information, please see the United States Clinical Trials Registry.

MMRF Patient Symposium To Be Held In Los Angeles – The Multiple Myeloma Research Foundation (MMRF) will hold a symposium for myeloma patients and their families on February 26 at Intercontinental Los Angeles Century City. After a basic introduction to multiple myeloma, leading myeloma experts will speak about managing bone disease, treatment options for myeloma patients, and clinical trials. A panel of myeloma experts will also be available to answer questions from patients and family members. Registration will begin at 8:30 a.m., and the program will conclude at 2:30 p.m. For more information or to register, please visit the MMRF website.

For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.

News»

[ by | Dec 8, 2010 6:08 pm | Comments Off ]
Zometa May Improve Survival In Myeloma Patients (ASH 2010)

According to the results of a large Phase 3 clinical trial, Zometa increases overall and progression-free survival rates among multiple myeloma patients compared to Bonefos and is more effective in preventing bone loss and fractures.  Additonally, the trial found that inclusion of thalidomide as part of an induction regimen further improved responses. 

Dr. Gareth Morgan of the Royal Marsden Hospital in London presented the results, recently published in The Lancet (abstract), at the American Society of Hematology (ASH) annual meeting in Orlando today.

“I think it is incredibly compelling …

Read the full story »

News»

[ by | Updated: Nov 20, 2010 3:00 p.m. | Comments Off ]
Xgeva Receives FDA Approval For Bone Disease In Solid Tumors, But Not Multiple Myeloma

The U.S. Food and Drug Administration announced earlier today that denosumab, which will be marketed by Amgen under the brand name Xgeva, has been approved to help prevent fractures and to slow bone disease in patients with solid tumors. It was not approved at this time for use in patients with multiple myeloma.

“It wasn’t approved [for myeloma] because the Xgeva-treated subset of multiple myeloma patients had more deaths than the control arm,” said Erica Jefferson, a spokesperson for the Food and Drug Administration (FDA).

Xgeva is an antibody that …

Read the full story »